This article is more than 5 years old. Information may no longer be current.

Interventional Spine announces FDA clearance of new fusion device

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Interventional Spine recently announced the receipt of U.S. Food and Drug Administration clearance for its Lateral Opticage Expandable Intervertebral Body Fusion Device.

The Opticage, which can used with the company’s PerX360 System, is indicated for use with autogenous bone graft in patients with degenerative disc disease at one or two contiguous levels from L2-S1. The lumbar intervertebral body fusion device can be implanted via posterior, transforaminal or lateral approaches, according to a company press release.
The device is now part of Interventional Spine’s line of Opticage Expandable Interbody Fusion Devices cleared for transforaminal lumbar interbody fusion earlier this year.

Reference: www.i-spineinc.com.